Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant's mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/18/16 | $45,000,000 | Series A |
Third Rock Ventures | undisclosed |
| 07/17/18 | $62,000,000 | Series B |
Agent Capital Cowen Investments  Eventide Asset Management Menlo Ventures Schroder Adveq SCubed Capital | undisclosed |
| 03/03/20 | $100,000,000 | Series C |
Agent Capital Cormorant Asset Management Cowen Healthcare Investments Eventide Asset Management Farallon Capital Management Logos Capital Menlo Ventures Novartis Redmile Group Schroder Adveq SCubed Capital Surveyor Capital | undisclosed |
